{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:55:25Z","timestamp":1789584925803,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40256-025-00726-z","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T18:04:32Z","timestamp":1744913072000},"page":"491-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients"],"prefix":"10.1007","volume":"25","author":[{"given":"Mohammad","family":"Tanashat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan A.","family":"Al-Ajlouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuelazm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obieda","family":"Altobaishat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almothana","family":"Manasrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4261-0638","authenticated-orcid":false,"given":"Mustafa","family":"Turkmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8917-671X","authenticated-orcid":false,"given":"Mohamed","family":"Abouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","volume":"92","author":"YC Chooi","year":"2019","unstructured":"Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metab Clin Exp. 2019;92:6\u201310. https:\/\/doi.org\/10.1016\/j.metabol.2018.09.005.","journal-title":"Metab Clin Exp"},{"key":"726_CR2","doi-asserted-by":"publisher","DOI":"10.1017\/gheg.2020.2","volume":"5","author":"CT Austvoll","year":"2020","unstructured":"Austvoll CT, Gallo V, Montag D. Health impact of the Anthropocene: the complex relationship between gut microbiota, epigenetics, and human health, using obesity as an example. Glob Health Epidemiol Genom. 2020;5: e2. https:\/\/doi.org\/10.1017\/gheg.2020.2.","journal-title":"Glob Health Epidemiol Genom"},{"key":"726_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.681581","author":"M Li","year":"2021","unstructured":"Li M, Qian M, Kyler K, Xu J. Adipose tissue-endothelial cell interactions in obesity-induced endothelial dysfunction. Front Cardiovasc Med. 2021. https:\/\/doi.org\/10.3389\/fcvm.2021.681581.","journal-title":"Front Cardiovasc Med"},{"key":"726_CR4","doi-asserted-by":"publisher","DOI":"10.2196\/20788","volume":"9","author":"Y Lin","year":"2020","unstructured":"Lin Y, Bailey JE, Surbhi S, Shuvo SA, Jackson CD, Chen M, Price-Haywood EG, Mann J, Fort D, Burton J, Sandlin R, Castillo A, Mei H, Smith P, Leak C, Le P, Monnette AM, Shi L. Continuity of care for patients with obesity-associated chronic conditions: protocol for a multisite retrospective cohort study. JMIR Res Protoc. 2020;9: e20788. https:\/\/doi.org\/10.2196\/20788.","journal-title":"JMIR Res. Protoc."},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1111\/ene.14881","volume":"28","author":"P Zhang","year":"2021","unstructured":"Zhang P, Yan X-L, Qu Y, Guo Z-N, Yang Y. Association between abnormal body weight and stroke outcome: a meta-analysis and systematic review. Eur J Neurol. 2021;28:2552\u201364. https:\/\/doi.org\/10.1111\/ene.14881.","journal-title":"Eur J Neurol"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11906-010-0099-1","volume":"12","author":"SA Morse","year":"2010","unstructured":"Morse SA, Gulati R, Reisin E. The obesity paradox and cardiovascular disease. Curr Hypertens Rep. 2010;12:120\u20136. https:\/\/doi.org\/10.1007\/s11906-010-0099-1.","journal-title":"Curr Hypertens Rep"},{"key":"726_CR7","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41598-018-21751-w","volume":"8","author":"K Nakashima","year":"2018","unstructured":"Nakashima K, Kaneto H, Shimoda M, Kimura T, Kaku K. Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1\/GLP-1R complex functioning through intra-islet paracrine mechanism. Sci Rep. 2018;8:3725. https:\/\/doi.org\/10.1038\/s41598-018-21751-w.","journal-title":"Sci Rep"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"2200130","DOI":"10.1002\/adbi.202200130","volume":"7","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Huang S, Li C, Qiao Y, Liu Q, Chen T, Wang J, Liu Y. Glucagon-like peptide-1 (GLP-1) rescue diabetic cardiac dysfuntions in human ipsc-derived cardiomyocytes. Adv Biol. 2023;7:2200130. https:\/\/doi.org\/10.1002\/adbi.202200130.","journal-title":"Adv Biol"},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/dmrr.1080","volume":"26","author":"W Glaesner","year":"2010","unstructured":"Glaesner W, Mark Vick A, Millican R, Ellis B, Tschang S-H, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N, Etgen G, Bumol T. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287\u201396. https:\/\/doi.org\/10.1002\/dmrr.1080.","journal-title":"Diabetes Metab Res Rev"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/HCO.0000000000001084","volume":"38","author":"RM Goldenberg","year":"2023","unstructured":"Goldenberg RM, Teoh H, Verma S. Glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data. Curr Opin Cardiol. 2023;38:539. https:\/\/doi.org\/10.1097\/HCO.0000000000001084.","journal-title":"Curr Opin Cardiol"},{"key":"726_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/dom.13490","volume":"21","author":"G Elbaz-Greener","year":"2019","unstructured":"Elbaz-Greener G, Bloch O, Kumets I, Blatt A, Rapoport MJ. Endogenous glucagon-like peptide-1 system response is impaired during ST-elevation myocardial infarction in type 2 diabetes patients, Diabetes. Obes Metab. 2019;21:194\u20138. https:\/\/doi.org\/10.1111\/dom.13490.","journal-title":"Obes Metab"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/pharmacy9040186","volume":"9","author":"J Prudencio","year":"2021","unstructured":"Prudencio J, Cajudoy P, Waddell D. Optimization of medication regimens in patients with type 2 diabetes and clinical atherosclerotic cardiovascular disease. Pharm Basel Switz. 2021;9:186. https:\/\/doi.org\/10.3390\/pharmacy9040186.","journal-title":"Pharm. Basel Switz."},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146:1882\u201394. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059595.","journal-title":"Circulation"},{"key":"726_CR14","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1111\/j.1755-5922.2010.00256.x","volume":"30","author":"T Okerson","year":"2012","unstructured":"Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30:e146-155. https:\/\/doi.org\/10.1111\/j.1755-5922.2010.00256.x.","journal-title":"Cardiovasc Ther"},{"key":"726_CR15","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2337\/db12-1025","volume":"62","author":"D Wang","year":"2013","unstructured":"Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, Wang H, Ren J, Cao F. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP\/PKA\/Rho-dependent mechanism. Diabetes. 2013;62:1697\u2013708. https:\/\/doi.org\/10.2337\/db12-1025.","journal-title":"Diabetes"},{"key":"726_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1463-1326.2010.01345.x","volume":"13","author":"P Anagnostis","year":"2011","unstructured":"Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control, Diabetes. Obes Metab. 2011;13:302\u201312. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01345.x.","journal-title":"Obes Metab"},{"key":"726_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023570","volume":"6","author":"W Bao","year":"2011","unstructured":"Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Albiglutide, a long lasting glucagon-like peptide-1 analog protects the rat heart against ischemia\/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS ONE. 2011;6: e23570. https:\/\/doi.org\/10.1371\/journal.pone.0023570.","journal-title":"PLoS ONE"},{"key":"726_CR18","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.2337\/db17-1212","volume":"67","author":"J Moellmann","year":"2018","unstructured":"Moellmann J, Klinkhammer BM, Onstein J, St\u00f6hr R, Jankowski V, Jankowski J, Lebherz C, Tacke F, Marx N, Boor P, Lehrke M. Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy. Diabetes. 2018;67:2410\u20139. https:\/\/doi.org\/10.2337\/db17-1212.","journal-title":"Diabetes"},{"key":"726_CR19","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1111\/dom.13472","volume":"20","author":"S Diebold","year":"2018","unstructured":"Diebold S, Moellmann J, Kahles F, Haj-Yehia E, Liehn EA, Nickel A, Lebherz C, Maack C, Marx N, Lehrke M. Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity, Diabetes. Obes Metab. 2018;20:2911\u20138. https:\/\/doi.org\/10.1111\/dom.13472.","journal-title":"Obes Metab"},{"key":"726_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"726_CR21","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook of systematic reviews of interventions., John Wiley & Sons, Ltd, Chichester (UK), 2019. https:\/\/training.cochrane.org\/handbook. Accessed 11 Oct 2023.","DOI":"10.1002\/9781119536604"},{"key":"726_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"key":"726_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ, GRADE Working Group. What is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ. 2008;336:995\u20138. https:\/\/doi.org\/10.1136\/bmj.39490.551019.BE.","journal-title":"BMJ"},{"key":"726_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"726_CR26","unstructured":"Joanne E McKenzie, Sue E Brennan, Rebecca E Ryan, Hilary J Thomson, Renea V Johnston, Chapter 9: Summarizing study characteristics and preparing for synthesis, in: Cochrane Handb. Syst. Rev. Interv., Cochrane, 2023. https:\/\/training.cochrane.org\/handbook\/current\/chapter-09. Accessed 4 Dec 2023."},{"key":"726_CR27","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29:2909\u201318. https:\/\/doi.org\/10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"key":"726_CR28","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean MEJ, NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study, Lancet Lond. Engl. 2009;374:1606\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(09)61375-1.","journal-title":"Engl"},{"key":"726_CR29","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2005","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2005;40:1310\u20139. https:\/\/doi.org\/10.1038\/ijo.2016.52.","journal-title":"Int J Obes"},{"key":"726_CR30","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, J\u00f3dar E, Kandler K, Rigas G, Wadden TA, Wharton S. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"key":"726_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"726_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S, STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10:193\u2013206. https:\/\/doi.org\/10.1016\/S2213-8587(22)00008-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"726_CR33","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietil\u00e4inen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet Lond Engl. 2021;398:2160\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(21)01751-7.","journal-title":"Lancet Lond. Engl."},{"key":"726_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15407","author":"Y Li","year":"2023","unstructured":"Li Y, Cheng Z, Lu W, Li P, Jiang H, Yang J, Xu J, Zhang C, Zhang L, Wang Y, Bian F, Guo W, Yu X, Chen X, Zhao D, Feng B, Qu S, Qin J, Zhang Y, Wang L, Cheng H, Mu Y. Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Obes Metab. 2023. https:\/\/doi.org\/10.1111\/dom.15407.","journal-title":"Diabetes Obes Metab"},{"key":"726_CR35","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torn\u00f8e CW, Ryan DH. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"key":"726_CR36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","volume":"9","author":"IJ Neeland","year":"2021","unstructured":"Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, Rodder S, Pandey A, Joshi PH. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9:595\u2013605. https:\/\/doi.org\/10.1016\/S2213-8587(21)00179-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"726_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet Lond Engl. 2018;392:637\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(18)31773-2.","journal-title":"Lancet Lond Engl"},{"key":"726_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, Le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH, SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"key":"726_CR39","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/dom.13824","volume":"21","author":"RE Pratley","year":"2019","unstructured":"Pratley RE, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Jacob S, Yoon K-H. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study, Diabetes. Obes Metab. 2019;21:2429\u201339. https:\/\/doi.org\/10.1111\/dom.13824.","journal-title":"Obes Metab"},{"key":"726_CR40","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D, STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414\u201325. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"key":"726_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT, STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327:138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"key":"726_CR42","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2337\/dc09-1203","volume":"33","author":"J Rosenstock","year":"2010","unstructured":"Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33:1173\u20135. https:\/\/doi.org\/10.2337\/dc09-1203.","journal-title":"Diabetes Care"},{"key":"726_CR43","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O\u2019Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT. STEP 3 investigators, effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403\u201313. https:\/\/doi.org\/10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"key":"726_CR44","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2302392.","journal-title":"N Engl J Med"},{"key":"726_CR45","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"726_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1479164113481817","volume":"10","author":"T Gaspari","year":"2013","unstructured":"Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE\u2212\/\u2212 mouse model. Diab Vasc Dis Res. 2013;10:353\u201360. https:\/\/doi.org\/10.1177\/1479164113481817.","journal-title":"Diab Vasc Dis Res"},{"key":"726_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.904626","author":"M Almutairi","year":"2022","unstructured":"Almutairi M, Chan JSF, Ussher JR. New therapeutic options for type 2 diabetes mellitus and their impact against ischemic heart disease. Front Physiol. 2022. https:\/\/doi.org\/10.3389\/fphys.2022.904626.","journal-title":"Front Physiol"},{"key":"726_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1968785","volume":"2019","author":"Q-F Xiong","year":"2019","unstructured":"Xiong Q-F, Fan S-H, Li X-W, Niu Y, Wang J, Zhang X, Chen Y-F, Shi Y-W, Zhang L-H. GLP-1 relaxes rat coronary arteries by enhancing ATP-sensitive potassium channel currents. Cardiol Res Pract. 2019;2019: e1968785. https:\/\/doi.org\/10.1155\/2019\/1968785.","journal-title":"Cardiol Res Pract"},{"key":"726_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1159\/000527675","volume":"69","author":"Y Xu","year":"2023","unstructured":"Xu Y, Chen C, Yang Y, Ai S, Ao W, Kong L, Zhang Y, Li J, Xiao J. Activation of the vascular smooth muscle GLP-1\/NCX1 pathway regulates cytoplasmic Ca2+ homeostasis and improves blood pressure variability in hypertension. Gerontology. 2023;69:603\u201314. https:\/\/doi.org\/10.1159\/000527675.","journal-title":"Gerontology"},{"key":"726_CR50","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-0031-1271777","volume":"43","author":"BB Dokken","year":"2011","unstructured":"Dokken BB, Bonte LRL, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011;43:300\u20135. https:\/\/doi.org\/10.1055\/s-0031-1271777.","journal-title":"Horm Metab Res"},{"key":"726_CR51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4093\/dmj.2011.35.5.437","volume":"35","author":"JS Yoon","year":"2011","unstructured":"Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J. 2011;35:437\u201343. https:\/\/doi.org\/10.4093\/dmj.2011.35.5.437.","journal-title":"Diabetes Metab J"},{"key":"726_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.13888","volume":"22","author":"E Mannucci","year":"2020","unstructured":"Mannucci E, Dicembrini I, Nreu B, Monami M. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: an updated meta-analysis and subgroup analysis of randomized controlled trials, Diabetes. Obes Metab. 2020;22:203\u201311. https:\/\/doi.org\/10.1111\/dom.13888.","journal-title":"Obes Metab"},{"key":"726_CR53","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319:1580\u201391. https:\/\/doi.org\/10.1001\/jama.2018.3024.","journal-title":"JAMA"},{"key":"726_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, Ceriello A, Chiodini P, Esposito K. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189. https:\/\/doi.org\/10.1186\/s12933-021-01366-8.","journal-title":"Cardiovasc Diabetol"},{"key":"726_CR55","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1055\/a-1844-1176","volume":"54","author":"X Guo","year":"2022","unstructured":"Guo X, Zhou Z, Lyu X, Xu H, Zhu H, Pan H, Wang L, Yang H, Gong F. The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis. Horm Metab Res. 2022;54:458\u201371. https:\/\/doi.org\/10.1055\/a-1844-1176.","journal-title":"Horm Metab Res"},{"key":"726_CR56","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6616693","volume":"2021","author":"X Lyu","year":"2021","unstructured":"Lyu X, Lyu T, Wang X, Zhu H, Pan H, Wang L, Yang H, Gong F. The antiobesity effect of GLP-1 receptor agonists alone or in combination with metformin in overweight \/obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Int J Endocrinol. 2021;2021: e6616693. https:\/\/doi.org\/10.1155\/2021\/6616693.","journal-title":"Int J Endocrinol"},{"key":"726_CR57","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/oby.23563","volume":"30","author":"S Sarma","year":"2022","unstructured":"Sarma S, Palcu P. Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis. Obesity. 2022;30:2111\u201321. https:\/\/doi.org\/10.1002\/oby.23563.","journal-title":"Obesity"},{"key":"726_CR58","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/biomedicines11030669","volume":"11","author":"D Patoulias","year":"2023","unstructured":"Patoulias D, Michailidis T, Dimosiari A, Fragakis N, Tse G, Rizzo M. Effect of glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: an updated systematic review and meta-analysis of randomized controlled trials. Biomedicines. 2023;11:669. https:\/\/doi.org\/10.3390\/biomedicines11030669.","journal-title":"Biomedicines"},{"key":"726_CR59","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.3892\/etm.2020.8714","volume":"20","author":"RA Iorga","year":"2020","unstructured":"Iorga RA, Bacalbasa N, Carsote M, Bratu OG, Stanescu AMA, Bungau S, Pantis C, Diaconu CC. Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Exp Ther Med. 2020;20:2396\u2013400. https:\/\/doi.org\/10.3892\/etm.2020.8714.","journal-title":"Exp Ther Med"},{"key":"726_CR60","doi-asserted-by":"publisher","first-page":"1004044","DOI":"10.3389\/fendo.2022.1004044","volume":"13","author":"B Gallwitz","year":"2022","unstructured":"Gallwitz B. Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol. 2022;13:1004044. https:\/\/doi.org\/10.3389\/fendo.2022.1004044.","journal-title":"Front Endocrinol"},{"key":"726_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2013-000013","volume":"2","author":"T Angelopoulos","year":"2014","unstructured":"Angelopoulos T, Kokkinos A, Liaskos C, Tentolouris N, Alexiadou K, Miras AD, Mourouzis I, Perrea D, Pantos C, Katsilambros N, Bloom SR, le Roux CW. The effect of slow spaced eating on hunger and satiety in overweight and obese patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2014;2: e000013. https:\/\/doi.org\/10.1136\/bmjdrc-2013-000013.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"726_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13177","volume":"22","author":"KR Chadda","year":"2021","unstructured":"Chadda KR, Cheng TS, Ong KK. GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis. Obes Rev. 2021;22: e13177. https:\/\/doi.org\/10.1111\/obr.13177.","journal-title":"Obes Rev"},{"key":"726_CR63","doi-asserted-by":"publisher","unstructured":"Zhang F, Tang L, Zhang Y et al. Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with\nand without overweight\/obesity: meta-analysis of randomized controlled trials. Sci Rep 2017;7:15997.\nhttps:\/\/doi.org\/10.1038\/s41598-017-16018-9.","DOI":"10.1038\/s41598-017-16018-9"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00726-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00726-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00726-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:08:01Z","timestamp":1751699281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00726-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00726-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"18 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mohammad Tanashat, Yazan Al-Ajlouni, Mohamed Abuelazm, Obieda Altobaishat, Almothana Manasrah, Mustafa Turkmani, Ubaid Khan, and Mohamed Abouzid have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability:"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"M. Tanashat, M. Abuelazm, and M. Abouzid: conceptualization and methodology. O. Altobaishat, A. Manasrah, M. Tanashat, U. Khan, M. Turkmani, and M. Abuelazm: investigation and data curation. M. Abouzid: formal analysis, software, and resources. Y.A. Al-Ajlouni and M. Abouzid: Writing - original draft. M. Abuelazm, and M. Abouzid: Supervision. M. Abuelazm, M. Turkmani,\u00a0and M. Abouzid: Project administration. M. Abuelazm and M. Abouzid: Writing - review and editing. All authors read and approved the final content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}